Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 13/20 | 0.66 |
| ▸ | ITGA4 | P13612 | 13/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.58 |
| ▸ | MMP8 | P22894 | 1/20 | 0.52 |
| ▸ | MMP12 | P39900 | 1/20 | 0.52 |
| ▸ | MMP13 | P45452 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2988722 | 1.00 | ITGB1 (0.66) | ITGB1ITGA4ALDH1A1HTTITGB7 | |
| SCHEMBL3904073 | 0.95 | ITGB1 (0.67) | ITGB1ITGA4ALDH1A1HTTITGB7 | |
| SCHEMBL3904078 | 0.95 | ITGB1 (0.67) | ITGB1ITGA4ALDH1A1HTTITGB7 | |
| SCHEMBL5201269 | 0.91 | ITGB1 (0.58) | ITGB1ITGA4ITGB7 | |
| SCHEMBL5201278 | 0.91 | ITGB1 (0.58) | ITGB1ITGA4ITGB7 | |
| SCHEMBL3717708 | 0.85 | ALDH1A1 (0.71) | ALDH1A1HTTMMP8MMP12MMP13 | |
| SCHEMBL3710420 | 0.85 | ALDH1A1 (0.71) | ALDH1A1HTTMMP8MMP12MMP13 | |
| SCHEMBL2706446 | 0.82 | HCRTR1 (0.61) | ITGB1ITGA4ALDH1A1HTTMMP8 | |
| SCHEMBL2706441 | 0.82 | HCRTR1 (0.61) | ITGB1ITGA4ALDH1A1HTTMMP8 | |
| SCHEMBL2704403 | 0.81 | ALDH1A1 (0.64) | ALDH1A1HTTMMP8MMP12MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7777042-B2 | N-sulfonylpipecolic acid derivative FKBP binding composition and pharmaceutical use thereof | AVENTIS PHARMACEUTICALS INC. (US) | 2010-08-17 | — | — | US | claimed |
| US-20080139556-A1 | FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2008-06-12 | — | — | US | claimed |
| EP-1778637-A2 | FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF | Aventis Pharmaceuticals, Inc. (US) | 2007-05-02 | — | — | EP | claimed |
| WO-2006012256-A2 | FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2006-02-02 | — | — | WO | claimed |
| US-7777042-B2 | N-sulfonylpipecolic acid derivative FKBP binding composition and pharmaceutical use thereof | AVENTIS PHARMACEUTICALS INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20080139556-A1 | FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2008-06-12 | — | — | US | disclosed |
| EP-1778637-A2 | FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF | Aventis Pharmaceuticals, Inc. (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006012256-A2 | FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139556-A1 | FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF | FKBP1A, FKBP1B, FKBP3 | ITGB1 3840/4885ITGA4 4199/4885ALDH1A1 3038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.